Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.41 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908147 | 0.90 | CA5A (0.40) | P2RX3P2RX4P2RX2P2RY1P2RY11 | |
| SCHEMBL5908150 | 0.90 | NT5E (0.45) | P2RY1P2RY11 | |
| SCHEMBL5694106 | 0.90 | POLB (0.45) | P2RY12POLBENPP1P2RY1P2RY11 | |
| SCHEMBL5694105 | 0.87 | POLB (0.39) | P2RX3P2RX4P2RX2POLBP2RY1 | |
| SCHEMBL5694039 | 0.86 | P2RX3 (0.51) | P2RX3P2RX4P2RX2P2RY12ENPP1 | |
| SCHEMBL5694075 | 0.84 | POLB (0.41) | POLB | |
| SCHEMBL5694044 | 0.84 | POLG (0.38) | POLB | |
| SCHEMBL17860588 | 0.82 | ADORA1 (0.40) | P2RY12POLBP2RY1 | |
| SCHEMBL5694100 | 0.81 | NT5E (0.48) | P2RY1P2RY11 | |
| SCHEMBL5694199 | 0.80 | CA5A (0.42) | P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | P2RX3 4092/4885P2RX4 4376/4885P2RX2 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.